Literature DB >> 7529217

Natural history of hepatitis C.

K Kiyosawa1, E Tanaka, T Sodeyama, S Furuta.   

Abstract

With advances in tools for the diagnosis of hepatitis C virus (HCV) infection, it has become easier to evaluate the natural course of hepatitis C. Although HCV infection initially occurs in adult individuals, in most patients with acute hepatitis C (68%) it develops into chronic hepatitis. Once chronic hepatitis is established, the rate of spontaneous cure of the liver disease is very rare (below 2%). The duration from the onset of acute hepatitis until the time of diagnosis of cirrhosis of the liver and of hepatocellular carcinoma is about 20 and 30 years, respectively. The long-term clinical course of hepatitis C is divided into the three phases of acute, silent, and reactivated. The acute phase lasts from the onset of disease until 2-3 years thereafter, and the silent phase which follows lasts for 10-15 years. In the silent phase, the serum transferase level remains relatively low, below 100 IU/l, and is sometimes within the normal range. In the reactivated phase, the level of serum aminotransferase increases and remains at a high or moderate level until hepatocellular carcinoma develops. The mechanism of the chronicity of hepatitis C is unknown. However, recent advances in molecular analysis may soon elucidate this. Successive antigenic change of the HCV E2/NS1 hypervariable domain as a result of mutations may represent a mechanism by which this virus escapes the host immunosurveillance system, as well as a mechanism of its chronicity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7529217     DOI: 10.1159/000150363

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  4 in total

1.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.

Authors:  P Farci; A Shimoda; D Wong; T Cabezon; D De Gioannis; A Strazzera; Y Shimizu; M Shapiro; H J Alter; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

2.  Hepatitis virus infection and liver disease in injecting drug users who died suddenly.

Authors:  E A McCruden; K J Hillan; I C McKay; M T Cassidy; J C Clark
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

3.  Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases.

Authors:  Ayumi Sugiura; Satoru Joshita; Yuki Yamashita; Tomoo Yamazaki; Naoyuki Fujimori; Takefumi Kimura; Akihiro Matsumoto; Shuichi Wada; Hiromitsu Mori; Soichiro Shibata; Kaname Yoshizawa; Susumu Morita; Kiyoshi Furuta; Atsushi Kamijo; Akihiro Iijima; Satoko Kako; Atsushi Maruyama; Masakazu Kobayashi; Michiharu Komatsu; Makiko Matsumura; Chiharu Miyabayashi; Tetsuya Ichijo; Aki Takeuchi; Yuriko Koike; Yukio Gibo; Toshihisa Tsukadaira; Hiroyuki Inada; Yoshiyuki Nakano; Seiichi Usuda; Kendo Kiyosawa; Eiji Tanaka; Takeji Umemura
Journal:  Biomedicines       Date:  2020-04-03

4.  [Implication of mutation of hepatitis C virus 1b interferon sensitivity determining region(NS5A aa 2209-2248) response to interferon alpha therapy in patients with chronic hepatitis C].

Authors:  Z Tang; J Köck; D Moradpour; D Yang; L Hao; H Blum
Journal:  J Tongji Med Univ       Date:  1999
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.